Empresas›BOLT
BOLT · Bolt Biotherapeutics, Inc.
preparados farmaceuticos · CIK 0001641281
Bolt Biotherapeutics, Inc. (BOLT) cotiza en el NASDAQ y se dedica a preparados farmaceuticos. Aqui estan 2 documentos que ha presentado ante la SEC, desde 11 ago 2026. En sus informes aparecen frases que este sitio vigila: duda sustancial sobre la continuidad de la empresa y contrasplit de acciones. Estan citadas literalmente mas abajo.
- Documentos
- 2
- Ultimo
- 11 ago 2026
recogidos hasta hoy
Hecho relevante
Todavia no se publican los trimestres de caja ni la dilucion de esta empresa: hacen falta datos de sus informes que solo se recogen de las que se siguen de cerca. Lo que ves abajo son sus documentos tal y como los presento ante la SEC.
Documentos presentados ante la SEC
2026
- 8-KHecho relevanteEDGAR
- 10-QInforme trimestralEDGAR
Duda sustancial sobre la continuidad de la empresaver la frase en el documento (ingles)
…cash and cash equivalents and marketable securities of $18.1 million as of June 30, 2026 may be sufficient to fund our operations into first quarter 2027. As a result, we have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the issuance of the unaudited condensed consolidated financial statements. We evaluated our current cash position, historical results, forecasted cash flows and plans with regard…
Contrasplit de accionesver la frase en el documento (ingles)
…additional capital through equity or partnering will depend on the general economic environment in which it operates and its ability to achieve key milestones. Reverse Stock Split On June 6, 2025, the Company effected a 1-for-20 reverse stock split (the “Reverse Stock Split”) of its common stock. The par value per share and the number of authorized shares were not adjusted as a result of the Reverse Stock Split. The shares of common stock underlying…